In a hemodynamically stable patient after an acute coronary syndrome, how should beta‑blocker therapy be initiated, dosed, and monitored?

Beta-Blocker Therapy Post-ACS: Initiation, Dosing, and Monitoring

In hemodynamically stable patients after acute coronary syndrome, initiate low-dose oral beta-blocker therapy within 24 hours of diagnosis, then slowly titrate upward as blood pressure and heart rate permit, targeting a heart rate of 50-60 beats per minute. 1

Initiation Timing and Patient Selection

Start oral beta-blockers early (within 24 hours) in all ACS patients without contraindications 1. The 2025 ACC/AHA guidelines strongly recommend this approach based on evidence showing reduced reinfarction and ventricular arrhythmias 1. The 2021 ESC guidelines similarly recommend early initiation in patients with ongoing ischemic symptoms 2.

Critical contraindications to screen for before initiation:

• Acute heart failure (Killip class II-IV)
• Evidence of low cardiac output or cardiogenic shock risk
• PR interval >0.24 seconds
• Second- or third-degree heart block without pacemaker
• Severe bradycardia
• Active bronchospasm 1

If contraindications exist on presentation, reassess after 24 hours 1.

Dosing Strategy

Start low and go slow. The COMMIT trial demonstrated that high-dose intravenous beta-blockers (up to 15 mg IV metoprolol followed by 200 mg oral daily) increased cardiogenic shock risk, particularly in the first 24 hours 1. This finding fundamentally changed practice patterns.

Recommended approach:

• Begin with low-dose oral beta-blocker therapy
• Gradually escalate dose based on hemodynamic tolerance
• Target heart rate: 50-60 beats per minute 3
• Discontinue immediately if new or worsening heart failure symptoms develop 1

In practice, implementation of standardized ACS pathways has shown that mean discharge doses of metoprolol around 118 mg/day can be achieved safely, resulting in mean discharge heart rates of 67 bpm 3.

Monitoring Parameters

During titration, monitor:

• Heart rate (target 50-60 bpm)
• Blood pressure (ensure adequate perfusion)
• Signs/symptoms of heart failure
• Evidence of cardiogenic shock
• Bradycardia or heart block development

Achieving target heart rate matters: only 19% of patients in protocol-driven care achieved HR <60 bpm, but this was significantly better than non-protocol care (6%) 3.

Duration and Long-Term Considerations

The evidence base is evolving and shows important nuances:

The most recent and highest quality evidence comes from the 2025 BETAMI-DANBLOCK trial 4, which enrolled 5,574 patients with MI and LVEF ≥40%. This trial showed beta-blockers reduced the composite endpoint of death or major adverse cardiovascular events (14.2% vs 16.3%; HR 0.85,95% CI 0.75-0.98) over 3.5 years, driven primarily by reduced myocardial infarction (5.0% vs 6.7%; HR 0.73).

However, the benefit varies by left ventricular function:

• LVEF <40%: Clear benefit established; continue indefinitely 1
• LVEF 41-49% (mildly reduced): Observational data suggests benefit, though not studied in contemporary randomized trials 5. The 2026 REBOOT landmark analysis showed a non-significant trend toward benefit in the first year post-MI 6
• LVEF ≥50% (preserved): The BETAMI-DANBLOCK trial 4 supports use, contradicting earlier observational studies and the REDUCE-AMI findings 5

Key Pitfalls to Avoid

1. Avoid intravenous beta-blockers in the acute setting unless specifically managing tachyarrhythmias - the COMMIT trial showed increased cardiogenic shock with IV dosing 1

2. Don't use high initial doses - start low and titrate gradually to avoid hemodynamic compromise

3. Don't continue in patients developing heart failure - reassess frequently during hospitalization and discontinue if signs of decompensation appear 1

4. Don't assume all patients need indefinite therapy - while the 2025 BETAMI-DANBLOCK trial 4 supports longer-term use even with preserved LVEF, the REBOOT landmark analysis 6 suggests potential harm with higher doses in the chronic phase (>1 year post-MI)

Practical Algorithm

1. Within 24 hours of ACS diagnosis: Screen for contraindications
2. If no contraindications: Start low-dose oral beta-blocker (e.g., metoprolol 25 mg BID)
3. Daily assessment: Check HR, BP, heart failure signs
4. Titrate every 1-2 days: Increase dose if HR >60 bpm and hemodynamically stable
5. At discharge: Continue beta-blocker with target HR 50-60 bpm
6. Long-term: Continue indefinitely if LVEF <50%; consider ongoing benefit-risk assessment if LVEF ≥50% based on BETAMI-DANBLOCK results 4

The weight of current evidence, particularly the 2025 BETAMI-DANBLOCK trial 4 and guideline recommendations 1, supports beta-blocker initiation and continuation in most post-ACS patients regardless of ejection fraction, though the magnitude of benefit appears greatest in those with reduced LVEF.